title: Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
authors.affiliation: Fresenius Biotech GmbH, Frankfurter Ring 193a, D-80807 München, Munich, Germany. diane.seimetz@fresenius-biotech.com
authors.forename: Diane
authors.initials: D
authors.lastname: Seimetz
authors.forename: Horst
authors.initials: H
authors.lastname: Lindhofer
authors.forename: Carsten
authors.initials: C
authors.lastname: Bokemeyer